Journal Scans
Dose-Dense Paclitaxel Once a Week in Combination With Carboplatin Every 3 Weeks for Advanced Ovarian Cancer: A Phase 3, Open-Label, Randomised Controlled Trial
Weekly Paclitaxel Plus Carboplatin Demonstrates Survival Benefit in Advanced Ovarian Cancer
N Katsumata, M Yasuda, F Takahashi, S Isonishi, T Jobo, D Aoki, H Tsuda, T Sugiyama, S Kodama, E Kimura, K Ochiai, K Noda, for the Japanese Gynecologic Oncology Group
Yes
20090818
2009 Sept 18
Lancet
Dose-Dense Paclitaxel Once a Week in Combination With Carboplatin Every 3 Weeks for Advanced Ovarian Cancer: A Phase 3, Open-Label, Randomised Controlled Trial
Lancet. 2009 Sept 18; Epub ahead of print, N Katsumata, M Yasuda, F Takahashi, S Isonishi, T Jobo, D Aoki, H Tsuda, T Sugiyama, S Kodama, E Kimura, K Ochiai, K Noda, for the Japanese Gynecologic Oncology Group
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
Background: Paclitaxel and carboplatin given every 3 weeks is standard treatment for advanced ovarian carcinoma. Attempts to improve patient survival by including other drugs have yielded disappointing results. We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer. Methods: Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this...
